

SPECIAL SYMPOSIUM:

TARGETING INNATE IMMUNE SIGNALLING PATHWAYS

Sara I. Pai, M.D., Ph.D.

Professor of Otolaryngology-Head and Neck Surgery Yale University School of Medicine, New Haven, CT, USA

September 16, 2024




DECLARATION OF INTERESTS

Sara Pai:	
Consultant:	Abbvie, AstraZeneca, Cue Biopharma, G1 Therapeutics,
	Incendia, Inovio Pharmaceuticals, Merck Sharp & Dohme
	LLC, Oncolys, Recurrent Respiratory Papillomatosis Foundation,
	Replimmune, Sensei Bio, Scopus Biopharma
Grant/Research:	Abbvie, AstraZeneca, Cue Biopharma, Sensei, Tesaro
Educational Talks:	Merck Sharp & Dohme LLC
Investigator-Initiated Clinical Trial	s: ASTX Pharmaceuticals, AstraZeneca, Cue Biopharma,
	Eisai, Immune Design, Merck Sharp & Dohme LLC
Editorial Roles:	Senior Editor, Cancer Research
Travel Support:	Chan-Zuckerberg Institute, Merck Serono, Recurrent
	Respiratory Papillomatosis Foundation



Concept of Combinatorial Immunotherapy with ICB






Sara Pai, MD, PhD

Pardoll DM. *Nature Reviews* April 2012

Innate and Adaptive Immune Response




Dranoff G. Nature Reviews Jan 2004



Sara Pai, MD, PhD

Innate and Adaptive Immune Response




Dranoff G. Nature Reviews Jan 2004



Sara Pai, MD, PhD

Five key activities in DCs needed to stimulate T cells






Sara Pai, MD, PhD


Cao LL and Kagan JC. Immunity Oct 2023

Complex Tumor Microenvironment





Developing Combinatorial Strategies to Overcome Immune Resistance in Head and Neck Squamous Cell Carcinoma (NIH P01CA240239)



Specific Aim 1: Uncover both intrinsic and extrinsic mechanisms of immune resistance in HNSCC patients

Specific Aim 2: Develop rationale, novel combinatorial strategies that translate into clinically meaningful responses


Project 1: Improving antigenicity through epigenetic reprogramming (Pai)

ESMO 2024 867MO

Project 2: Redirecting pre-existing anti-viral immunity to HNSCCs with APECs (Mempel)

Project 3: Myeloid-lymphoid cell crosstalk in HNSCC therapy (Pittet)

Despite a Complex Tumor Microenvironment...






Sara Pai, MD, PhD

Bill R et al. Science Aug 2023

Our Immune System is Uniform Across Individuals




BARCELONA ESTO


Sara Pai, MD, PhD

Bill R et al. Science Aug 2023

CXCL9:SPP1 polarity of TAMs is a major contributor to the clinical outcome of HNSCCs


A






Genes with a fold-change > 3 relative to the next cell type identified for each major cell type.

D




Bill R et al, Science, Aug 2023

С



IFN-g Increases CXCL9+ TAM whereas Hypoxia Increases SPP1+ TAM Polarity



В


HN52 (TAM polarity: CS^h) Area with CXCL9+ TAMs Area with CXCL9+ TAMs Area with CXCL9- TAMs



Sara Pai, MD, PhD


Bill R et al. Science Aug 2023

CXCL9/SPP1 (C/S) Ratio is a Better Biomarker of Clinical Outcome than M1/M2 Markers



Bill R et al. Science Aug 2023

CXCL9:SPP1 Tumor-associated Macrophage Polarity Determines the Broader TME




Bill R et al. Science Aug 2023




Cytokines and Ligand:Receptor Pairs associated with CXCL9:SPP1 Tumor-associated Macrophage Polarity

-0.5 0 0.5




Bill R et al. Science Aug 2023

Innate and Adaptive Immune Response Programs






Innate and Adaptive Immune Response





Sara Pai, MD, PhD

Distinct Neutrophil States Exist



Sara Pai, MD, PhD

- Neutrophils can accumulate in tumors during successful immunotherapy
- Immunotherapy expands a distinct neutrophil state with an IFN-stimulated gene signature
- The neutrophil response requires IFN-g and IL-12
 from BATF3-dependent DCs
- ISG^{hi} (Sell^{hi} SiglecF^{lo}) neutrophil response is associated with better outcomes

Gungabeesoon et al, Cell March 2023 186:1448-1464



Conclusions


Innate immunity is the first line of defense against infection and/or cancer and can be harnessed to support adaptive immune responses.

Cells of the innate immune system are abundant yet complex with multiple molecular identities.

Targeting single molecule(s) within the innate signaling pathway(s) may be met with limited success based on the intricate soluble and cellular interactions within the tumor microenvironment.

Unveiling relevant innate immune programs may yield successful future targets.

CXCL9/SPP1 TAM polarity is associated with improved clinical outcomes and response to immunotherapy



National Institute of Health/National Cancer Institute Head and Neck Cancer Program Project Grant (P01 CA240239)



William Faquin, M.D., Ph.D. Director, Head and Neck Pathology, Massachusetts Eye and Ear



Chair, Dept of Onco-Immunology, ISREC, UNIGE

Cancer immunotherapy, lymphocyte and myeloid cell biology



Thorsten Mempel, M.D., Ph.D. Associate Director, Center for Immunology and Inflammatory Dis

Cellular immunology; T cell repertoire; Tregs; chemokines



Peter Sadow, M.D., Ph.D. Director, Head and Neck Pathology, MGH



Sara Pai, M.D., Ph.D.

Director, Translational Head & Neck Cancer Research

Cancer vaccines, HPV, head and neck cancer



Maureen Sartor, Ph.D. Professor, Univ of Michigan Computational Bioinformatics, Biostatistics



David Rimm, M.D., Ph.D.

Director Yale Pathology Tissue Services and Tissue Microarray ; Director, MSTP Training Program



Jeffrey Townsend, Ph.D.

Professor, Yale Evolutionary Bioinformatics, Genomics, Genetics, Epigenetics



Benjamin Judson, M.D., M.B.A.

Chief, Otolaryngology-Head and Neck Surgery, Head and Neck Cancer